Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,356 recalls, newest first

Class II · Moderate risk

Oxygen

cGMP Deviations

Terminated cGMP deviation Family Medical Supply Inc D-0106-2024
Class III · Low risk

V-FORCE Homeopathic

Incorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product label).

Terminated cGMP deviation Grato Holdings, Inc. D-0099-2024
Class II · Moderate risk

Strong Iodine Solution U.S.P.

CGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.

Terminated cGMP deviation Safecor Health, LLC NDC 48433-230-15 D-0082-2024
Class II · Moderate risk

Integrity Biochem HSC 70-VA

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0111-2024
Class II · Moderate risk

Integrity Biochem HSC70-LV

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0110-2024
Class II · Moderate risk

Integrity Biochem HSC 70-LM

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0109-2024
Class II · Moderate risk

Rufinamide Tablets

cGMP deviations: Batch was released prior to approval.

Terminated cGMP deviation Aurobindo Pharma USA Inc. NDC 59651-617-08 D-1088-2023
Class II · Moderate risk

Rufinamide Tablets

cGMP deviations: Batch was released prior to approval.

Terminated cGMP deviation Aurobindo Pharma USA Inc. NDC 59651-616-08 D-1087-2023
Class II · Moderate risk

ROcuronium Bromide 50 mg/5 mL

CGMP Violations- that spaces adjacent to the production area may have been compromised at the time of production.

Terminated cGMP deviation New England Life Care, Inc. dba Advanced Compounding Solutions D-0928-2023
Class II · Moderate risk

SUCCINYLcholine Chloride 200 mg/10mL

CGMP Violations- that spaces adjacent to the production area may have been compromised at the time of production.

Terminated cGMP deviation New England Life Care, Inc. dba Advanced Compounding Solutions D-0926-2023

Recalls by year